Journal
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE
Volume 55, Issue 5, Pages 886-891Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.TA.0000066184.20808.A5
Keywords
hemostasis; hemorrhage; platelets; factor VIIa
Categories
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048320] Funding Source: NIH RePORTER
- NHLBI NIH HHS [R01 HL 48320] Funding Source: Medline
Ask authors/readers for more resources
Background: Recombinant coagulation factor VIIa (FVIIa) is, approved for treating hemophiliacs with inhibitors. High-dose FVIIa has also been used off-label to manage hemorrhage in trauma and surgical patients, many of whom also develop hypothermia and acidosis. Methods: We examined the activity of FVIIa on phospholipid vesicles in the presence and absence of tissue factor (TF) and on platelets as a function of temperature and pH. Results: FVIIa activity on phospholipids and platelets was not reduced at 33degreesC compared with 37degreesC. The activity of FVIIa/TF was reduced by 20% at 33degreesC compared with 37degreesC. A pH decrease from 7.4 to 7.0 reduced the activity of FVIIa by over 90% and FVIIa/TF by over 60%. Conclusion:. FVIIa should be effective in enhancing hemostasis in hypothermic patients. However, because the activity of FVIIa is so dramatically affected by pH, its efficacy may be reduced in acidotic patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available